Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

Autor: Patrick Gavin Kehoe, Nicholas Turner, Beth Howden, Lina Jarutyte, Shona Louise Clegg, Ian Brian Malone, Josephine Barnes, Casper Nielsen, Carole Hélène Sudre, Aileen Wilson, Ngoc Jade Thai, Peter Sinclair Blair, Elizabeth Coulthard, Janet Athene Lane, Peter Passmore, Jodi Taylor, Henk-Jan Mutsaerts, David Lee Thomas, Nick Charles Fox, Ian Wilkinson, Yoav Ben-Shlomo, Kirsty Harkness, Tarun Kuruvilla, Rupert McShane, Peter Connelly, Gordon Duncan, Lucy Calvert, Alasdair Lawrie, Matthew Sheridan, Eric Jackson, Bernard Udeze, Stephen Pearson, Tobias Langheinrich, Suvarna Wagle, Joseph Butchart, Ajay Macharouthu, Andrew Donaldson, Wendy Neil, Vivek Pattan, David Findlay, Alan Thomas, Robert Barber, Andrew Byrne, Madhusudan Dalvi, Rashi Negi, Bernadette McGuinness

Publikováno v: The Lancet. Neurology
Lancet Neurology, 20(11), 895-906. Lancet Publishing Group
Kehoe, P G, Turner, N, Howden, B, Jarutyte, L, Clegg, S L, Malone, I B, Barnes, J, Nielsen, C, Sudre, C H, Wilson, A, Thai, N J, Blair, P S, Coulthard, E, Lane, J A, Passmore, P, Taylor, J, Mutsaerts, H-J, Thomas, D L, Fox, N C, Wilkinson, I, Ben-Shlomo, Y & RADAR investigators 2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial) : a double-blind, randomised, placebo-controlled, phase 2 trial ', Lancet Neurology, vol. 20, no. 11, pp. 895-906 . https://doi.org/10.1016/S1474-4422(21)00263-5
RADAR investigators 2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial ', The Lancet. Neurology, vol. 20, no. 11, pp. 895-906 . https://doi.org/10.1016/S1474-4422(21)00263-5
2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial) : a double-blind, randomised, placebo-controlled, phase 2 trial ', Lancet Neurology, vol. 20, no. 11, pp. 895-906 . https://doi.org/10.1016/S1474-4422(21)00263-5
Kehoe, P G, Turner, N, Howden, B, Jarutyte, L, Clegg, S L, Malone, I B, Barnes, J, Nielsen, C, Sudre, C H, Wilson, A, Thai, N J, Blair, P S, Coulthard, E, Lane, J A, Passmore, P, Taylor, J, Mutsaerts, H-J, Thomas, D L, Fox, N C, Wilkinson, I & Ben-Shlomo, Y 2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial ', Lancet Neurology, vol. 20, no. 11, pp. 895-906 .

BACKGROUND: Drugs modifying angiotensin II signalling could reduce Alzheimer's disease pathology, thus decreasing the rate of disease progression. We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a28429bb9f725cd7e59ecafb894961
http://europepmc.org/articles/PMC8528717

Machine learning prediction for magnetic properties of Sm-Fe-N based alloys produced by melt spinning

Autor: Emma Lucy Calvert, Hiroyuki Hosokawa, Koji Shimojima

Publikováno v: Journal of Magnetism and Magnetic Materials. 526:167651

In this paper, we applied machine learning (ML) to the materials processing of Sm-Fe-N magnetic powders produced by melt spinning. Neural Networks (NN) were used to generate ML models. Data were collected from relevant papers and patents, amounting t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83f54453c175629a0a42ade19d7ccbef
https://doi.org/10.1016/j.jmmm.2020.167651